Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Polyzois Makras

Showing results (41-50 of 139) with videos related to

Pageof 14
Sort By:
International Journal of Molecular Sciences|April 26, 2020
Gender Predilection in Sporadic Parathyroid AdenomasMaria P Yavropoulou, Athanasios D Anastasilakis, Argyro Panagiotakou, et al.
Metabolism: Clinical and Experimental|January 29, 2019
Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?Athanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 8, 2024
The comparative effect of teriparatide and denosumab on activins, follistatins, and inhibins in women with postmenopausal osteoporosisAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 26, 2025
No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trialPolyzois Makras, Maria P Yavropoulou, Athanasios D Anastasilakis, et al.
The American Surgeon|March 15, 2011
Extensive and concurrent infiltration of an ectopic intrathoracic thyroid and thyroid gland by papillary thyroid cancerGeorge H Sakorafas, Christos Lappas, Aikaterini Mastoraki, et al.
Calcified Tissue International|March 2, 2018
Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?Athanasios D Anastasilakis, Symeon Tournis, Maria P Yavropoulou, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|November 21, 2020
Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be EnoughAthanasios D Anastasilakis, Georgios Trovas, Alexia Balanika, et al.
Clinical Endocrinology|March 5, 2013
Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosisPolyzois Makras, Stergios A Polyzos, Athanasios Papatheodorou, et al.
Trends in Endocrinology and Metabolism: TEM|June 30, 2007
Endocrine manifestations in Langerhans cell histiocytosisPolyzois Makras, Krystallenia I Alexandraki, George P Chrousos, et al.
Medical Hypotheses|April 13, 2011
Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesisAthanasios D Anastasilakis, Stergios A Polyzos, Chrysostomos D Anastasilakis, et al.
Pageof 14

Showing results (41-50 of 139) with videos related to

Sort By:
Pageof 14
International Journal of Molecular Sciences|April 26, 2020
Gender Predilection in Sporadic Parathyroid AdenomasMaria P Yavropoulou, Athanasios D Anastasilakis, Argyro Panagiotakou, et al.
Metabolism: Clinical and Experimental|January 29, 2019
Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?Athanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 8, 2024
The comparative effect of teriparatide and denosumab on activins, follistatins, and inhibins in women with postmenopausal osteoporosisAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 26, 2025
No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trialPolyzois Makras, Maria P Yavropoulou, Athanasios D Anastasilakis, et al.
The American Surgeon|March 15, 2011
Extensive and concurrent infiltration of an ectopic intrathoracic thyroid and thyroid gland by papillary thyroid cancerGeorge H Sakorafas, Christos Lappas, Aikaterini Mastoraki, et al.
Calcified Tissue International|March 2, 2018
Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?Athanasios D Anastasilakis, Symeon Tournis, Maria P Yavropoulou, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|November 21, 2020
Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be EnoughAthanasios D Anastasilakis, Georgios Trovas, Alexia Balanika, et al.
Clinical Endocrinology|March 5, 2013
Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosisPolyzois Makras, Stergios A Polyzos, Athanasios Papatheodorou, et al.
Trends in Endocrinology and Metabolism: TEM|June 30, 2007
Endocrine manifestations in Langerhans cell histiocytosisPolyzois Makras, Krystallenia I Alexandraki, George P Chrousos, et al.
Medical Hypotheses|April 13, 2011
Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesisAthanasios D Anastasilakis, Stergios A Polyzos, Chrysostomos D Anastasilakis, et al.
Pageof 14